0
0
LOS ANGELES — Researchers at UCLA have developed a simple, low-cost blood test capable of detecting signals from multiple cancers, liver diseases, and other organ abnormalities in a single sample. According to a landmark study published in the Proceedings of the National Academy of Sciences in April 2026, the test—dubbed MethylScan—analyzes chemical “methylation” patterns on DNA fragments circulating in the blood. This breakthrough offers a potential “liquid biopsy” that not only flags abnormal tissue activity but helps clinicians pinpoint exactly where in the body a disease may be developing.
How the MethylScan Test Works: Reading the Body’s “Liquid Biopsy”
The science behind MethylScan relies on a biological phenomenon known as cell-free DNA (cfDNA). When cells in the body die, they shed small fragments of their genetic code into the bloodstream. These fragments act as a continuous biological status report for every organ in the system.
While many earlier liquid biopsies focused on searching for rare genetic mutations—which can be like finding a needle in a haystack—MethylScan targets DNA methylation. These are chemical “tags” that attach to DNA to regulate gene expression, essentially turning genes on or off.
“Methylation patterns are like a cellular fingerprint,” explains Dr. Elena Rossi, an oncologist not involved in the UCLA study. “These patterns differ significantly between tissue types and change drastically when a cell becomes cancerous or diseased. By reading these tags, we aren’t just looking for cancer; we are looking at the overall health of the organ.”
Because these signatures are so specific, the test can theoretically detect more than just tumors; it can identify liver inflammation, scarring (cirrhosis), and other forms of organ stress that traditional cancer-only tests might miss.
Overcoming the “Noise”: A Cheaper, More Efficient Design
One of the primary hurdles in bringing multi-cancer early detection (MCED) tests to the masses has been the astronomical cost. Most current assays require “deep sequencing,” a process of reading the entire genome repeatedly to find faint disease signals amidst a sea of normal DNA. Approximately 80% to 90% of cfDNA in the blood comes from healthy blood cells, creating significant background “noise.”
The UCLA team bypassed this roadblock through a novel two-step process:
-
Selective Removal: Using specialized enzymes, they cut away unmethylated DNA fragments, which primarily originate from healthy blood cells.
-
Targeted Enrichment: They then used a hybridization panel to “capture” and amplify the methylated DNA from solid organs.
By filtering out the noise, the researchers achieved a high level of accuracy with significantly less data. The study suggests that this method could reduce the cost of sequencing to under $20 per sample at current market prices, making it a viable candidate for routine annual screenings.
Early Results: Testing More Than 1,000 Patients
To validate the technology, researchers analyzed blood samples from 1,061 participants. This diverse group included patients with:
-
Liver, lung, ovarian, and stomach cancers.
-
Chronic conditions such as Hepatitis B and C.
-
Alcohol-related and metabolic-associated liver diseases.
-
Benign lung nodules and healthy controls.
The team utilized machine-learning algorithms to parse the complex methylation data. The results were promising: for multi-cancer detection, MethylScan achieved a 63% overall sensitivity at a 98% specificity. This means that while the test correctly identified roughly three out of five cancers, it maintained a very low false-positive rate of just 2%.
In high-risk populations, such as those with cirrhosis undergoing liver-cancer surveillance, the test’s performance climbed significantly, identifying nearly 80% of liver cancers.
Beyond Cancer: Pinpointing the “Tissue of Origin”
A common criticism of early blood tests was that they could tell a patient they had cancer, but not where it was. MethylScan addresses this by mapping methylation patterns back to known tissue-specific signatures.
In the clinical trial, the test correctly identified whether a signal was coming from the liver or the lungs with high precision. Furthermore, it demonstrated a “health radar” function, distinguishing between viral hepatitis and metabolic liver disease with 85% accuracy. This suggests that in the future, blood-based profiling could reduce the need for painful and invasive liver biopsies.
The Broader Landscape of Early Detection
MethylScan joins an emerging class of MCED tests aimed at catching “silent killers”—cancers like pancreatic and ovarian for which there are currently no routine screenings.
Recent modeling from Harvard University suggests that if these tests are implemented affordably, they could shift a substantial portion of cancer diagnoses to earlier, more treatable stages. Projections indicate a possible 45% reduction in late-stage diagnoses over the next decade.
However, health experts emphasize that these tests are complementary. They are intended to work alongside, not replace, “gold standard” screenings like:
-
Mammography for breast cancer.
-
Colonoscopy for colorectal cancer.
-
Low-dose CT scans for high-risk smokers.
Limitations and Expert Caution
Despite the enthusiasm, the medical community remains cautiously optimistic. A sensitivity of 55% for early-stage cancers means that nearly half of early tumors may still go undetected by this test alone.
“We have to be careful about the ‘all-clear’ signal,” says Dr. Marcus Thorne, a public health researcher. “A negative result on a blood test does not mean you are cancer-free. Furthermore, we need to see how this performs in the general, asymptomatic population—not just in a controlled study group—before we can call it a standard of care.”
There is also the risk of “over-diagnosis,” where the test finds microscopic lesions that might never have caused harm, leading to unnecessary anxiety and invasive follow-up procedures.
What This Means for You
For now, MethylScan remains in the research and validation phase. It is not yet available at your local clinic.
For Clinicians: This study provides a roadmap for using cfDNA to monitor “pan-organ” health, potentially moving medicine toward a model of “proactive surveillance” rather than “reactive treatment.”
For Patients: The best path to health remains following established screening guidelines. However, the dawn of the $20 multi-disease blood test suggests a future where your annual physical might include a comprehensive “radar sweep” of your internal organs, catching life-threatening issues long before symptoms appear.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://medicalxpress.com/news/2026-04-multiple-cancers-diseases-blood-sample.html
